ACG case reports journalApr 10, 2026

Symptom remission in ulcerative colitis linked to semaglutide treatment

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

Semaglutide initiation was followed by symptomatic remission and mucosal healing in a patient with left-sided and poorly controlled diabetes.

Evidence

This single case report describes a 42-year-old woman with left-sided UC whose persistent symptoms on maximal mesalamine improved to clinical remission by 8 weeks after semaglutide, with improved fecal calprotectin and follow-up colonoscopy findings.

Caveat

A single uncontrolled case cannot show that semaglutide caused remission or define its role apart from mesalamine and the patient's metabolic changes.

Simplified

(UC) often requires immunosuppressive therapy for remission. are used for diabetes and obesity, although their role in UC is unclear. We report a 42-year-old woman with left-sided UC and poorly controlled diabetes who achieved remission after initiating semaglutide. Despite persistent symptoms on maximal mesalamine, she declined immunosuppression. After semaglutide initiation, she achieved clinical remission by 8 weeks, with improved fecal calprotectin, metabolic parameters, and mucosal healing on follow-up colonoscopy. This case suggests a potential adjunctive role for glucagon-like peptide-1 receptor agonists in UC.

Key numbers

420 µg/g to 115 µg/g

Fecal Calprotectin Decrease

Fecal calprotectin levels before and after semaglutide initiation

12 mg/L to 3 mg/L

C-Reactive Protein Decrease

C-reactive protein levels before and after treatment

Weight Loss

Body weight reduction after 4 months of semaglutide therapy

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Symptom remission in ulcerative colitis linked to semaglutide treatment

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief